One problem limiting the development of long-term gene replacement therapy is gene silencing. A variety of experiments have implicated DNA methylation and histone deacetylation in gene silencing and shown that the agents 5-azacytidine (5-Aza) and trichostatin A (TSA) are able to reverse these effects. To begin to investigate clinically relevant strategies to reverse silencing with these drugs, we transduced the MEL and FDCP-1 hematopoietic cell lines with Moloney murine leukemia virus (MMLV) and Harvey murine sarcoma virus (HMSV)-based retroviral vectors carrying the ␤-galactosidase/neomycin resistance fusion gene (␤-geo). Fifty-one clones were isolated under G418 selection over 2 weeks and then allowed to grow without selection as
Introduction
Retroviral vectors have been the most common method of gene transfer in clinical gene therapy trials. 1 This is largely due to their ability to integrate stably and efficiently into the genome of target cells. However, experiments in both human and model systems have identified a number of problems which must be overcome before retrovirus-based gene transfer can become therapeutically useful beyond a limited set of clinical situations. One major obstacle has been a lack of consistent, high-level expression of retrovirally transferred genes. One cause of this inadequate expression appears to be transcriptional silencing, or the gradual loss of gene expression over time despite the presence of intact vector sequences. This loss of gene expression is not the result of a gradual decrease in expression in all cells of a clonal population, but is due to a complete loss of expression in an increasing proportion of cells within the population. 2 Similar silencing is also seen following integration of genes transferred by other viral and nonviral vectors. It has been suggested that the silencing of integrated retroviral sequences is a host defense mechanism against foreign DNA elements. ␤-gal activity was monitored over time. More than 80% of these clones showed significant silencing over a period of 70-80 days. The clones were then exposed to a wide range of 5-Aza and TSA concentrations, both alone and in combination, in an effort to reverse silencing. Despite demonstration that the agents were able to decrease DNA methylation and increase histone acetylation, significant reversal of long-term silencing was not seen under any experimental condition. These results suggest that long-term retroviral silencing involves mechanisms in addition to DNA methylation and histone acetylation and that new pharmacologic strategies are needed to overcome the silencing process. Gene Therapy (2000) 7, 653-663. noma (EC) cells, embryonic stem (ES) cells and murine hematopoietic stem cells. While the exact mechanisms which mediate silencing remain largely unknown, numerous studies have established that retroviral silencing is strongly associated with methylation of integrated viral DNA. [4] [5] [6] [7] [8] DNA methylation is mediated by the enzyme DNA methyltransferase 9 and occurs at cytosine residues within CpG sequences throughout the mammalian genome. 10 De novo methylation was originally found to be associated with retroviral silencing in mice and EC cells. 5, 6 Vector methylation has also been associated with silencing in other cell types including murine fibroblasts, myoblasts and bone marrow stem cells. 2, 8, 11, 12 The binding of a repressor protein to a retroviral negative regulatory element has also been shown to precede methylation and subsequent silencing of heterologous genes. 13, 14 More recent studies have shown that mutational inactivation of repressive cis elements within the MMLV vector which lead to increased expression also results in decreased methylation of LTR sequences. [15] [16] [17] These results and the recent description of a family of embryonic cell specific de novo methylases 18 implicate DNA methylation in retroviral silencing.
While little work regarding histone deacetylation in the context of retroviral vector silencing has been reported, it appears to be involved in general transcriptional silencing and may act in conjunction with DNA methylation. Acetylation occurs on the lysine rich amino terminal tails of histones and is thought to allow increased accessibility of transcription factors to gene regulatory elements. 19 Previous experiments have demonstrated that hypoacetylation of histones associated with specific genes correlates with gene silencing in yeast and human X chromosome inactivation [20] [21] [22] and that histone deacetylation leads to transcriptional repression of specific mammalian genes. 23 More recent evidence suggests that acetylation status has a causal role in maintenance of transcription since histone acetyltransferase activity is associated with eukaryotic transcription factors such as Gcn5, CBP/p300 and TAF II 250. 24 Recently a functional association between DNA methylation, histone acetylation and gene regulation has been described. MeCP 2 , a transcriptional repressor which specifically binds methylated DNA, associates with histone deacetylases through Sin3A, a repressive cofactor, to yield repression of gene expression. 25, 26 It has also been shown in the fungus Neurospora that inhibition of histone deacetylases can reverse repressed expression of methylated DNA. 27 Previous attempts to prevent silencing of viral vectors have largely followed two strategies. In the first, specific sequences within the retroviral vector which mediate silencing have been identified and mutated. These alterations have resulted in decreased silencing in tissue culture and murine models of gene transfer but have not completely eliminated the process. 17, 28, 29 A second strategy has involved attempts to prevent or reverse gene silencing pharmacologically. These efforts have primarily employed agents which inhibit DNA methylation or histone deacetylation. 2, 6, [30] [31] [32] [33] [34] [35] The drug 5-azacytidine (5-Aza) is a nucleoside analog which is incorporated into cellular DNA and irreversibly inhibits DNA methyltransferase by forming a covalent complex in the catalytic site of the enzyme. 36 This agent is used clinically to treat leukemia and the myelodysplastic syndromes and has been used experimentally to treat ␤-thalassemia and sickle cell disease. [37] [38] [39] Some of the earliest applications of 5-Aza to the study of retroviral silencing demonstrated that 5-Aza was able to revert the MMLV provirus to an infectious state after its expression had been silenced in EC cells and mice. 6, 30 While 5-Aza has since been successfully used to reactivate silenced gene expression from MMLV-based retroviral vectors in a variety of cell lines and experimental contexts, most experiments have focused on short-term silencing which takes place within days following retroviral transduction. 2, 14, [31] [32] [33] In the current report we have specifically studied the ability of 5-Aza to reverse long-term retroviral silencing which occurs over several weeks and may be the result of a distinct process.
Trichostatin A (TSA) is a potent, specific inhibitor of histone deacetylase activity which has recently been utilized to study reactivation of silenced viral constructs. Chen et al 34 observed that adeno-associated viral (AAV) silencing could be reversed by treatment with TSA and sodium butyrate, another less specific histone deacetylase inhibitor. These inhibitors have also been used to prevent silencing in several mammalian cell lines that have been transduced with a baculovirus-based vector. 35 To the best of our knowledge the use of this agent specifically to reverse retroviral vector silencing has not been reported.
Because therapeutically beneficial levels of expression from integrated gene transfer vectors have been difficult to achieve, pharmacologic strategies to prevent or reverse gene silencing could be of clinical value. This approach would be particularly relevant to the treatment of monogenic diseases in which life-long gene expression following transfer into stem cells, or other long-lived cells, is a goal. We have begun to evaluate specific pharmacologic strategies by producing clonal hematopoietic cell lines containing silenced MMLV and HMSV-based vectors carrying the ␤-geo reporter gene. Using a therapeutically relevant model of retroviral vector transduction, clonal selection and silencing we have assessed the abilities of 5-Aza and TSA, alone and in combination, specifically to reverse long-term silencing of integrated retroviral vectors. This type of silencing, which occurs over several weeks, has received less attention than short-term silencing, yet is likely to be relevant to the successful development of gene replacement therapy.
Results
Long-term silencing of retroviral vectors The initial goal of this project was to develop a system to study pharmacologic strategies to reverse long-term retroviral silencing in hematopoietic cells. Our system was designed to model a clinical gene therapy approach in which retrovirally transduced cells are initially selected in vitro and then returned to the recipient where gene expression continues under non-selective conditions. We began by transducing two hematopoietic cell lines, FDCP-1 and MEL. FDCP-1 is a murine factor dependent hematopoietic precursor cell line that was produced from long-term bone marrow culture in the presence of IL-3. 40 The MEL cell line is a murine erythroleukemia line that is capable of chemically induced erythroid differentiation. Two retroviral vectors, based on the MMLV and HMSV viruses, were constructed for these experiments. As shown in Figure 1 each vector carried the ␤-galactosidase (␤-gal)/neomycin phosphotransferase (neo) fusion gene (␤-geo) driven by the phosphoglycerate kinase promoter (pgk). 41 Following transduction, clones were selected with G418 over 2 weeks. Individual clones were then isolated and grown without selection. The clones were monitored for transgene silencing by measuring ␤-gal expression via flow cytometry 42 over a period of 70-80 days. Examples of histograms for silenced and non-silenced clones are shown in Figure 2a . The time-courses of silencing for several clones are shown in Figure 2b . As has been previously noted, silencing was characterized by a gradual decrease in the percentage of cells within each clonal population that expressed the reporter gene. Also, as is characteristic of long-term silencing, this process occurred over several weeks. 
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Silencing data for all clones are summarized in Table 1 . We initially chose two different cell lines and two different vectors in the hope that at least one combination would yield significant silencing. By 80 days after selection 91% of MEL clones and 72% of FDCP-1 lines had less than 50% of cells expressing ␤-gal activity, while 73% of MEL and 55% of FDCP-1 clones showed Ͼ75% of cells without activity after this time period. While not statistically significant, there appears to be a trend for the combination of the HMSV vector in MEL cells to be more susceptible to silencing (P = 0.06, 2 test). Before performing experiments to investigate the pharmacologic reversal of retroviral silencing we first determined whether silencing was due to the loss or rearrangement of vector DNA by probing Southern blots for the intact ␤-geo gene ( Figure 3 ). Genomic DNA was digested with HindIII and XhoI which should yield a 4.7 kb band corresponding to an intact ␤-geo gene. Representative results from both silenced and non-silenced clones are shown. When initial (I) and late (L, у90 days following selection) banding patterns were compared, no loss of signal was detected in any cell line. Initial samples were unavailable for silenced clones FM1 and FM6 but strong signals are present after silencing. The only two clones to show changes in banding patterns were FH3 and FM8. While this may have been due to clonal evolution during the experiment, neither of these clones underwent silencing. These experiments indicate that the silencing observed in our system is not the result of loss or rearrangement of integrated vector sequences and should therefore be potentially reversible.
5-Azacytidine and TSA treatment of silenced clones
The next step in our analysis was to determine whether 5-Aza and TSA alone, or in combination, could reverse long-term silencing in our system. To determine appropriate concentrations of 5-Aza and TSA, drug titration experiments were performed ( Figure 4 ). Because 5-Aza has a short half-life it is typically administered to patients by continuous infusion or daily subcutaneous injection over several days. [37] [38] [39] 43, 44 To model these treatment schedules we treated our cell cultures on a daily basis. Similarly, because our goal was to study potentially clinically relevant effects, we initially chose 5-Aza concentrations of 250 nm for the treatment of MEL cells and Representative results of the ␤-gal staining assay are shown in Figure 5 . In this Figure, the negative control is untransduced MEL cells and the positive control is the constitutively expressing FM7 clone. MH3 is a completely silenced clone. Clones in this experiment had been maintained in culture for approximately 150 days. ␤-Gal expression is not reactivated by 5-Aza, TSA or both drugs in combination, for the MH3 clone. The MM5 clone is the single example out of all clones tested which demonstrated significant reactivation of ␤-gal activity. When this clone was originally tested after 80 days in culture approximately 20% of cells exhibited ␤-gal activity. This was slightly increased at the 500 nm dose of 5-Aza. Other drug treatments did not increase expression. After 150 days in culture the MM5 clone was further silenced with only 1% of the cells showing ␤-gal activity. Drug treatment at this time point increased ␤-gal expression to 17% (5-Aza alone), 19% (TSA alone) and 22% (5-Aza + TSA). These treatments return the long-term MM5 clone to its previous expression level of approximately 20% (Table 2, Figure 5) .
Results of all drug treatment experiments are summarized in Table 2 . During the course of this experiment the clones treated with 5-Aza, TSA and the 5-Aza/TSA combination were in culture approximately 60, 90 and 120 days, respectively. Clones were initially treated with the chosen doses of 250 nm 5-Aza for the MEL cells, 500 nm 5-Aza for the FDCP-1 cells and 10 nm TSA for both cell lines (Figure 4) . In all cases, no significant reversal of silencing was seen with these doses. As noted above, these initial concentrations were chosen because they resulted in definite physiologic effects (growth inhibition) but not in significant cell death. Because some previous Gene Therapy studies which have demonstrated reversal of retroviral silencing used higher concentrations of 5-Aza, we also tested concentrations of 500 nm for MEL cells and 2 m for FDCP-1 cells. Again, even at these higher concentrations, no reversal of silencing was seen. Decreased expression was observed in some non-silenced clones treated at these higher concentrations and with the combination of 5-Aza and TSA (clones MM8, FH3, FH5 and FM8). We attribute this decreased expression to cytotoxicity which occurred at these higher concentrations (data not shown). Selected clones were also tested at higher concentrations of 5-Aza (5 m) and TSA (3 m). As expected from our drug titration experiments, these treatments resulted in the death of virtually all cells, but again no evidence of reactivation was seen during the course of the experiment (data not shown). The results from the in situ ␤-gal staining assay indicate that in the great majority of cases, when 5-Aza and TSA are used alone or in combination, they are unable to reverse long-term retroviral silencing.
Activity of 5-azacytidine and trichostatin A Based on previously reported experiments we had expected that 5-Aza or TSA would reverse retroviral silencing in our system. Because of the unexpected result that neither agent was able to reverse long-term silencing we wanted to verify that the drugs were actually inhibiting methylation of vector DNA sequences and deacetylation of vector-associated histones. We first tested the ability of 5-Aza to inhibit DNA methylation by the methylation sensitive restriction enzyme assay ( Figure 6 ). For this experiment we used ClaI, a methylation sensitive restriction endonuclease which digests within the ␤-geo gene. While other methylation sensitive restriction enzyme sites are present within the vectors, Silenced and non-silenced retrovirally transduced clones were treated with 5-Aza and TSA. the ClaI site was chosen because it is present within both vectors and because demonstration of decreased methylation at this site following 5-Aza treatment should be sufficient to verify the activity of the drug. Isolated genomic DNA from 5-Aza treated and untreated cells was digested with XbaI alone or in combination with ClaI. XbaI digestion alone yields a parental band of 4.4 kb regardless of methylation status, while the addition of ClaI yields a 3.1 kb band if the recognition sequence is unmethylated. An increase in the proportion of ClaI site digestion indicates that 5-Aza treatment has decreased DNA methylation at this site within the vector. The FM7 clone constitutively expresses ␤-gal at high levels (see Figure 5 and Table 2 ). Complete digestion of the ClaI site in this positive control clone indicates that the site is not methylated and that the restriction enzyme is present in excess. When two completely silenced clones, MH3 and FM6, were analyzed only a proportion of their vector sequences were methylated at this site. The Southern blots from this assay demonstrate again that the ␤-geo DNA is still present and intact in the silenced clones and that 5-Aza induces a dose-dependent decrease in methylation within the retroviral sequences. Therefore, the inability of 5-Aza to reverse long-term silencing does not appear to be due to an inability of the drug to decrease DNA methylation.
Similarly, a possible explanation for the inability of TSA to reverse silencing in our system is that the drug is unable to promote increased acetylation of histones associated with integrated vector sequences. We utilized the chromatin immunoprecipitation assay (ChIPs) [45] [46] [47] to test the ability of 10 nm TSA to increase acetylation of histones. In this assay, genomic DNA samples are sonicated to produce DNA fragments associated with a limited number of nucleosomes. The nucleosomes and their associated genomic DNA fragments are then incubated with an antibody to acetylated histone H4. DNA fragments associated with nucleosomes containing acetylated H4 are precipitated while DNA fragments associated with nucleosomes containing unacetylated histone H4 remain in the supernatant. The precipitated and supernatant DNA fragments are then isolated and applied to a slot blot which is probed with DNA sequences from the region of interest to determine the extent to which these sequences are associated with acetylated nucleosomes. In our experiments we have used the neo probe ( Figure 6 ) to determine the acetylation status of nucleosomes associated with integrated vector DNA and total MEL cellular DNA as a probe to determine the overall level of histone acetylation. Assays were performed with and without TSA treatment. Figure 7a depicts data from a representative experiment involving the completely silenced MH3 clone and the high expressing MM8 clone (Table 2 ). These results indicate that for both clones vector DNA is primarily associated with the immunoprecipitated (acetylated) nucleosome fraction. Conversely, total cellular DNA is mostly in the supernatant (unacetylated) fraction. This experiment was performed four times and the results were quantitated by phosphorimager analysis. The results of these experiments are summarized in Figure 7b and c. In Figure 7b , the percentages of vector and total DNA associated with acetylated histones when the clones are treated with and without TSA are compared. While relatively minor proportions of total DNA for both clones are associated with acetylated histones (11.4% for MH3, 12.6% for MM8), vector DNA in both silenced and nonsilenced clones is highly associated with acetylated DNA (73.8% for MH3, 79.2% for MM8). Changes in histone H4 acetylation are shown in Figure 7c . Here the percentage change in acetylation of vector and total DNA for each clone following TSA treatment is shown. While no sig- nificant change is seen in the acetylation status of chromatin associated with either of the vectors, an approximate two-fold increase in acetylation of total cellular DNA is seen for both clones.
To verify that our findings were not unique to MEL cells we also evaluated the completely silenced FH2 clone and the high-expressing FM7 clone (Table 2) . Here too, vector-associated chromatin was highly acetylated in both clones (71% for FH2, 70% for FM7) while total DNA was not (9.5% for FH2, 32% for FM7). As with the MEL clones, TSA treatment did not significantly alter the acetylated fraction of vector sequences but increased the FH2 total DNA acetylated fraction to 28%.
The results of histone acetylation experiments point to two major findings. First, we have verified that TSA, as applied in our experiments, is active in increasing total histone acetylation. A more surprising result is that the integrated retroviral sequences in the two clones we have Gene Therapy studied in detail are associated with hyperacetylated histones regardless of their silencing status.
Discussion
One problem that must be overcome before long-term gene replacement therapy can become clinically useful is the inability to obtain consistent, high-level expression of transferred genes. One cause of inadequate expression of stably integrated genes appears to be gene silencing. The original aim of this project was to devise a system in which we could optimize pharmacologic strategies using 5-Aza and TSA to reverse silencing of retroviral vectors in hematopoietic cell lines. We have found that treating our silenced clones with several different concentrations and combinations of 5-Aza and TSA is unable to demonstrate significant reversal of retroviral silencing despite ample evidence that these agents are able to reverse gene silencing in other experimental systems. The inability of these agents to reactivate silenced genes was not due to a lack of activity since the drugs were able to induce decreased DNA methylation and increased histone acetylation.
One potential explanation for our observations is our focus on long-term retroviral vector silencing. We chose this system because it has received relatively little experimental attention and because it is likely to be relevant to understanding the silencing of therapeutic gene transfer vectors. Several of the previous reports which have demonstrated that 5-Aza can increase retroviral vector expression were performed on clonal populations that displayed low levels of expression soon after viral transduction. 2, 14, 31, 32, 35 In this report, we have referred to this as short-term silencing to contrast it with our experimental design where silencing occurs over many weeks. Two previous studies in which 5-Aza was used to attempt to reverse silencing of a small number of clones whose expression gradually decreased over 60-80 days were also unable to demonstrate significant reactivation of silenced viral gene expression. 34, 48 These findings raise the possibility that short-term and long-term silencing are mechanistically different and that while 5-Aza may act to increase expression early in the silencing process, the drug is unable to reverse long-term silencing.
Other variables in experimental design which might explain our results include the administration schedule and concentration of 5-Aza used. In most reports 5-Aza is applied to cells as a single treatment. However, because the half-life of this agent is only a few hours, we administered it on a daily basis in a schedule which is similar to those used to treat patients with leukemia, myelodysplastic syndromes and the hemoglobinopathies. [37] [38] [39] 43, 44 In some reports 5-Aza concentrations as high as 4-5 m have been used to increase gene expression. 2, 31, 33 Yet, at these concentrations we noted markedly decreased cell viability and no reactivation of expression.
Much less experience is available for TSA and other inhibitors of histone deacetylase activity. The report of Chen et al 34 that focused on silencing of integrated AAV vectors showed a dramatic reactivation by TSA and sodium butyrate. Pikaart et al 49 have demonstrated the ability of TSA to reverse silencing of genes carried on integrated bacterial plasmids. However, at least in our experimental system, we have been unable to demonstrate reversal of long-term retroviral silencing with this agent. One possibility is that hypoacetylation of vectorassociated histones is not part of the silencing mechanism. Our data showing that both silenced and fully expressing vectors are primarily associated with acetylated histones suggests this possibility. If this is the case then it is unlikely that TSA would reverse silencing by changing vector chromatin structure. This finding also offers a likely explanation for our finding that TSA does not significantly increase acetylation of vector-associated histones. Because the histones are already highly acetylated before TSA treatment, further acetylation under our conditions may not be possible.
While a wide variety of experimental evidence links the silencing of integrated foreign genes to DNA methylation and histone deacetylation, the finding that longterm silenced vectors cannot be reactivated suggests that more than just these two mechanisms are involved. The binding of repressive factors to specific sites on the integrated DNA appears likely to be an initial step in the silencing process. 13, 14 Current evidence indicates that methylation of vector DNA CpG residues may be a later event. 50, 51 It is not clear where histone deacetylation might fit into the process of silencing. It seems likely that beyond the chromatin structure modifications of methylation and histone acetylation additional alterations may occur which 'lock' the vector gene into an inactive state. If correct, such a multi-step model of silencing suggests that the application of 5-Aza and/or TSA at different time points in the silencing process may be effective in preventing silencing. This appears to be the case for 5-Aza in some experimental systems. 2, 14, 31, 35 The use of these agents to inhibit specific steps in the silencing process may also allow determination of when in the silencing process methylation and histone deacetylation occur. The ability to manipulate the silencing pathway pharmacologically may also offer a potential means of regulating the expression of integrated therapeutic genes.
As gene therapy strategies which require long-term gene expression continue to evolve, gene silencing is likely to remain a problem. A more complete understanding of the silencing process will be needed before strategies to prevent it in the clinical setting can be devised. While the effects of viral cis-acting elements, DNA methylation and histone acetylation are still poorly understood, recent genetic experiments, largely in nonmammalian systems, are providing initial insights into a complex set of cellular systems which appear to mediate silencing of foreign gene expression. 52 These investigations hold promise for increasing our understanding of the mechanisms of gene transfer vector silencing and for the development of gene therapy strategies to overcome this problem.
Materials and methods

Tissue culture
The FDCP-1 cell line was carried in RPMI-1640 media containing 10% FBS, 10% WEHI conditioned media (contains IL-3) and 1% PSN antibiotic mixture. The MEL cell line was carried in IMEM media containing 10% FBS. The NIH 3T3 cell line, which was used to determine titer of the packaging cell lines, was carried in DMEM containing 10% calf serum. The amphotropic packaging cell line PA317 was selected in HAT media (DMEM, 10% FBS, 0.03 mm hypoxanthine, 0.001 mm amethopterin, 0.02 mm thymidine) for 5 days, selected in HT media (DMEM, 10% FBS, 0.03 mm hypoxanthine, 0.02 mm thymidine) for 4 days and then carried in DMEM with 10% FBS for at least a month. 53, 54 The ecotropic packaging cell line GP-E86 was carried in HXM media (DMEM with 10% newborn calf serum, 1% PSN, 15 g/ml hypoxanthine, 250 g/ml xanthine, 25 g/ml mycophenolic acid and 100-150 l of HCl to adjust the pH). 55 Media, serum and antibiotics were purchased from GIBCO/BRL (Bethesda, MD, USA) and chemicals were purchased from Sigma (St Louis, MO, USA).
Retroviral transduction
The ␤-geo gene (␤-galactosidase/neomycin phosphotransferase fusion gene; a kind gift of Dr Philip Soriano, Fred Hutchinson CRC, Seattle, WA, USA), driven by the phosphoglycerate kinase (pgk) promoter, 41 was subcloned into a HMSV-based retroviral vector 56 and the MMLV-based pG1 vector. 57 Both vectors were first stably transfected by calcium phosphate precipitation into the PA317 amphotropic packaging cell line (ATCC, Rockville, MD, USA). 53, 54 Conditioned medium from G418 selected cells was then used to transduce the ecotropic packaging cell line GP-E86. 55 The GP-E86 cells were then G418 selected and individual clones tested for titer by counting neomycin resistant NIH 3T3 cell colonies. Titers of the packaging cell lines chosen for subsequent experiments for both retroviral vectors were 9 × 10 5 CFU/ml. FDCP-1 and MEL cell lines were transduced with conditioned media from the packaging cell lines in the presence of 6 g/ml polybrene (Sigma). 58 Transduced cells were then G418 selected over 2 weeks and clones were picked for each combination of cell line and retrovirus. These clones were then removed from G418 and monitored for ␤-gal expression by flow cytometry. 42 Southern blot analysis DNA was isolated 59 from each of the retrovirally transduced clones immediately following G418 selection and after culturing for more than 90 days. Isolated DNA was digested with HindIII and XhoI, Southern blotted and probed with a BamHI-XbaI fragment of the neo gene. The HindIII-XhoI digest yields a 4.7 kb band from both retroviral vectors. Restriction enzymes were purchased from GIBCO/BRL.
Reversal of silencing experiments
To determine appropriate drug concentrations for the reversal experiments, MEL and FDCP-1 cells were treated with increasing concentrations of 5-Aza (NCI, Bethesda, MD, USA) and TSA (Sigma). Cells were plated at 1 × 10 5 cells/ml. 5-Aza was administered daily for 4 days at 50-2000 nm. TSA was applied at 5-50 nm on the first day of each 4-day experiment. Cells were counted daily by Coulter counter (Fullerton, CA, USA) to determine the effect of 5-Aza and TSA concentrations on cell proliferation. Cell viability was assessed by the MTS assay (Promega, Madison, WI, USA). For the reversal experiments retrovirally transduced clones were plated at 1 × 10 5 cells/ml. MEL clones were treated with 250 and 500 nm 5-Aza and FDCP-1 clones were treated with 500 and 2000 nm 5-Aza daily for 4 days. MEL and FDCP-1 clones were both treated with 10 nm TSA at the start of each experiment and then followed for 4 days. For combination drug treatments, MEL clones were treated with 250 nm 5-Aza and 10 nm TSA. For the FDCP-1 clones the concentrations were 10 nm TSA and 500 nm 5-Aza. Both untreated and treated cells were harvested each day and stained for ␤-gal expression with an in situ ␤-gal staining assay (Stratagene, Houston, TX, USA).
Methylation assay
Clones were plated at 1 × 10 5 cells/ml and treated with two concentrations of 5-Aza (MEL, 250 and 500 nm;
Gene Therapy FDCP-1, 500 and 2000 nm) daily for 4 days. Cells were then harvested and the DNA was isolated. Genomic DNA was digested with XbaI, alone and in combination with the methylation-sensitive restriction endonuclease ClaI. Digested DNA was then Southern blotted and probed with the radiolabeled neo gene probe. Bands were quantitated by densitometry and analyzed with NIH Image software.
Chromatin immunoprecipitation assay
Clones were plated at 1 × 10 5 cells/ml, treated with 10 nm TSA and allowed to grow for 4 days. The cells were then harvested, treated with 1% formaldehyde, lysed by sonication and incubated with anti-acetylated histone H4 antibody (Upstate Biotechnology, Lake Placid, NY, USA). 45, 46 The precipitated antibody-histone-DNA complex was isolated and cross-linking was reversed. The immunoprecipitated and supernatant DNA was then applied to a slot blot. The blot was first probed with the neo probe (Figure 3) , then stripped and reprobed with total sonicated DNA from MEL cells. Blots were analyzed on a phosphorimager with the Imagequant software. The percentage of vector or total DNA associated with the immunoprecipitated, acetylated fraction was calculated by dividing the signal for the precipitate (P) by the sum of the signals for the precipitate and the supernatant (S, non-acetylated). Percentage change in acetylation was calculated by dividing the percentage acetylation of the treated sample by the percentage acetylation of the untreated sample. Acetylation of the untreated sample is considered to be 100%. Probability was calculated using the Student's t test.
